



SOFIVA GENOMICS



Stock Code 6615

Investor Conference

2024 / 07 / 03

Chairman
Yi-Ning Su, MD. Ph.D

Disclaimer

All statements for investors contain information that represent, other than historical facts, SOFIVA's plans and forward-looking statements are based upon management's current assumptions.

Environmental changes and other important factors could cause actual results to differ materially from those expressed in our statements.

Investors should carefully consider the investment objectives and risks before investing.

SOFIVA - The Dual Operating Strategy

Maternal Fetal Medicine

Precision Cancer Medicine

Genetic Screening Category	Servicing Specialty	Target
Reproductive	IVF Center	IVF Embryo Screening
Prenatal	OB-GYN	Pre-pregnant couples Pregnant couples
Newborn	Pediatrics, Neonatology	Child Newborn
Cancer	Cancer-related Specialty	All Target Audience (Pre-Cancer & Patient)
Rare Disease	Genetics-related Specialty	All Target Audience
 Precision Medicine	Treatment-related Specialty	All Target Audience

Maternal Fetal Medicine and Precision Cancer Medicine One Stop Service

Reproductive

- **PGT-M**
- **PGT-A**
- **niPGT-A**

Rare Diseases

- **Hearing Loss Genetic Test v1.0/v2.0/v3.0**
- **Achondroplasia**
- **Osteogenesis Imperfecta**
- **Duchenne Muscular Dystrophy**
- **Customized Genetic Test**

Prenatal

- **NIPS**
- **Array**
- **Karyotyping**
- **Carrier Scan**
- **SMA Carrier Screening**
- **Fragile X Carrier Screening**
- **Thalassemia Carrier Screening**

Cancer

- **Cancer Monitor**
- **Cancer Scan v1.0/v2.0**
- **Cancer Risk v1.0/v2.0**
- **HPV test**

Newborn

- **Baby Scan**
- **Hearing Loss Genetic Screening**
- **CCHS Genetic Screening**
- **Congenital CMV Infection**

Precision Medicine

- **Atopic Dermatitis Genetic Screening**
- **HRD Status**
- **CGP Genetic Test**
- **BRCA1/2 Genetic Testing**
- **Endometrial Cancer Genetic Subtypes**
- **Prostate Cancer Genetic Testing**




Operating Strategy

Maternal and Fetal Health Product Revenue Trends - Steady Growth

113Q2 compared to 112Q2


Reproductive PGT-A+PGT-M

Stable




Prenatal NIPS v1.0/v2.0/v3.0

Growth
10%





Prenatal Array v1.0/v2.0/v3.0

Growth
3%



Maternal and Fetal Health Product Revenue Trends - Steady Growth

113Q2 compared to 112Q2



Operating Strategy-Integration of Policy and Needs Health Insurance Benefits of NGS

Testing

1. NGS Genetic Testing

SOFIVA

Specimen: Tissue, and Blood.
Over 15 of NGS genetic testing.

2. Clinical Needs

SOFIVA


ISO15189 and LDTs
certification.
Collaboration with over 190
clinics.

3. Policy

■ Health Insurance Benefits of Testing from 2024/5/1

SOFIVA

NGS lab included in National
Health Insurance coverage





NGS genetic testing

Clinical Needs

SOFIVA Genetic Testing

Testing		Multi-Specimen		Unique Features	Multi-Specialty
品項					適用科別
1	子宮內膜癌基因分型	6	組織 + 血液	市場獨家：子宮內膜癌治療	婦科
2	癌監控基因檢測 - 膽管癌	13	組織 or 血液	膽管癌：FDA 用藥 + 臨床試驗用藥	消化
3	癌監控基因檢測 - 泌尿道上皮癌	13	組織 or 血液	泌尿道上皮癌：FDA 用藥 + 臨床試驗用藥	Gynecology
4	Precision Medicine Hereditary Testing Cancer Monitoring		組織 or 血液	肺癌：FDA 用藥 + 臨床試驗用藥	胸腔
5			組織 or 血液	乳癌：FDA 用藥 + 臨床試驗用藥	Thoracic
6			組織 or 血液	Unique testing	直外
7			組織 + 血液		婦科 / 乳外 / 泌尿
8			Tissue	市場獨家：攝護腺癌治療	Breast Surgery
9				可用液態切片監控癌症復發	胸腔 / 乳外 / 直外
10			Blood	可用液態切片監控癌症復發 + FDA 用藥 + 臨床試驗	Colorectal Surgery
11				全球第一	全科別
12	癌風險 - BRCA1/2 基因檢測	2	組織 or 血液	外果癌 / 乳癌 / 攝護腺癌 / 膀胱癌 / 結直腸癌	Urology
13	癌風險 - 大腸癌基因檢測	2	Body Fluid	大腸癌相關：MMR 基因為主	直外
14	癌風險 - 婦癌基因檢測	44		婦科癌相關：HRR 基因為主	婦科 / 乳外 / 泌尿
15	癌風險基因檢測 v1.0	67	組織 or 血液	各癌別	Multi-Specialty
16	癌風險基因檢測 v2.0	151	組織 or 血液	各癌別	
17	癌監控基因檢測 v2.2	197	組織 + 血液	全方位：FDA 用藥 + 復發相關基因	全科別
18	癌監控基因檢測 v3.0	249	組織 + 血液	全方位：FDA 用藥 + 臨床試驗用藥 + 復發相關基因	全科別



Clinical Needs

Qualified Lab

SOFIVA Genomics Medical Laboratory

Certification qualifications

**ISO
15189**



Food and Drug Administration, Ministry of Health and Welfare Listing and registration



衛生福利部食品藥物管理署

精準醫療分子檢測實驗室列冊登錄資料

機構名稱：慧智基因醫事檢驗所(地址：臺北市中正區寶慶路 27 號 6 樓、8 樓)

機構負責人：連苡淨

實驗室名稱：慧智基因醫學實驗室(地址：臺北市中正區寶慶路 27 號)

實驗室負責人：洪加政 (實驗室品質主管：王志成)

列冊登錄編號：LDT0008

列冊有效期間：110 年 9 月 28 日至 113 年 9 月 27 日止

列冊範圍：


項次	檢測名稱	分析標的	技術項目	服務範圍
1	非侵入性產前染色體篩檢	1. 檢體型態：血液。 2. 標的：胎兒第 13、18、21 對染色體及性染色體之基因體。	次世代定序	非侵入性胎兒染色體基因檢測
2	次世代定序胚胎著床前染色體篩檢	1. 檢體型態：胚胎細胞。 2. 標的：人類 23 對染色體之基因體。	次世代定序	生殖細胞突變
3	癌症基因突變檢測	1. 檢體型態：血液、組織(FFPE)。 2. 基因數：249 (附表 1)	次世代定序	體細胞突變

Clinical Collaboration

Integration of Clinical Needs

Clinical Collaboration: **Over 190 Clinics**

Medical Center: Over **10**
Local Hospital: Over **100**




Compliance with Clinical Standards:

Pathological
Sections



Report Information,
Genetic Counseling



Bioinformati
cs Analysis

Report
Discussion



Health Insurance Benefits

NGS Genetic Testing

Health Insurance Benefits Testing

From 2024/5/1

NGS Genetic

19種癌症基因檢測 納入健保給付



14 Solid Tumor 5 Hematology

不良症狀群(MDS)、急性淋巴芽細胞白血病(B-ALL 及 T-ALL)、
B細胞淋巴瘤(BCL)*及T或NK細胞血癌與
淋巴瘤(NKTL)*

註 ① NGS 檢測給付以檢測結果有對應「具藥證的標靶藥物」
且「效果明確之癌別及檢測基因」為優先

② 7大類癌症★專家共識建議採單基因檢測



3類套組 定額給付

醫病共享決策 各癌別終生給付一次

BRCA testing

10000

Small panel (≤ 100 genes)

20000

Large panel (> 100 genes)

30000

可再次檢測 (不包含癌症轉移)

② NGS 檢測結果須上傳至健保署，未來有新標靶
藥物納入健保給付，不需重新檢測，可直接
比對資料庫，把握用藥黃金期，提升治療效益
及降低民眾經濟負擔



SOFIVA Genomics - Tests meet the NGS reimbursement criteria

More than 10 testing

Meet the health insurance reimbursement criteria for various cancers

檢測名稱	基因數	肺癌	三陰性乳癌 / 胰臟癌	卵巢 / 輸卵管 / 腹膜癌	攝護腺癌	NTRK 腫瘤	膽管癌	下咽癌 / 甲狀腺髓質癌
癌監控肺癌	26	☆☆						☆☆
癌監控乳癌	26					10,000 20,000 30,000		☆☆
癌監控 v1.0	31	☆☆						☆☆
癌監控 v2.1	77	☆☆						☆☆
癌監控 v2.2	197							☆☆
癌監控 v3.0	249	☆☆☆		☆	☆			☆☆☆
CGP	324	☆☆☆		☆	☆	☆☆☆	☆☆☆	☆☆☆
BRCA1/2	2		☆	☆	☆			
HRD	28			☆	☆			
攝護腺癌檢測	30		☆	☆	☆			
癌風險	44~151		☆	☆	☆			



Health Insurance Benefits

Medicine

Health Insurance Benefits of Medicine

National Policy

SOFIVA Testing

Gene	Medicine	Cancer Type	SOFIVA
BRCA1/2	 Niraparib	Ovarian, Fallopian Tube, and Peritoneal Cancer	BRCA1/2
	 AGEEKA	Prostate Cancer	
	 Talazoparib	Breast Cancer	
HRD	 Olaparib	Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Prostate Cancer, Breast Cancer	HRD Status
FGFR3	 Erdafitinib	Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Prostate Cancer, Breast Cancer	Cancer Monitor
KRAS	 Sotorasib	Lung Cancer	
NTRK	 Larotrectinib	Pediatric Cancer + 13 Types of Adult Cancers	CGP Testing



Strategic Alliance

Instrument, Pharmaceutical

Biomedical Industry Chain - Cross-Industry Strategic Alliances


Testing

Upstream
Instruments,
Reagents



illumina

Midstream
Testing
Services



SOFIVA
GENOMICS
慧智基因

Industry
Strategic
Alliances

Downstream
End Users



Medicine

Upstream
Drug
Development

Pharmaceutical
Company



Midstream
Clinical Trials

Downstream
Clinical Use


SOFIVA
GENOMICS

A stylized DNA double helix structure is positioned horizontally across the top of the slide. It features light blue lines for the sugar-phosphate backbones and various colored spheres (yellow, blue, green, red) representing the nitrogenous bases. The helix is partially obscured by the large text in the center.

Operating Performance

Operational Performance

Statements of Comprehensive Income of last 3 years




(In Thousands of New Taiwan Dollars)			
	2021	2022	2023
Revenue	508,415	495,775	466,797
Gross Profit	176,813	148,988	129,908
Gross Profit (%)	34.78%	30.05%	27.83%
Opreating Income	35,240	3,787	(15,882)
Total Non-Opreating Income	28,453	43,562	24,785
Pre-Tax Income	63,693	47,349	8,903
Net Income	56,769	43,153	11,923
EPS	2.68	2.00	0.54

Revenue Trend : The Last 10 Quarters

(In Thousands of New Taiwan Dollars)


Revenues of Last 10 Quarters



Revenue Trend : The Last 6 Months

Revenues of Last 6 Months

(In Thousands of New Taiwan Dollars)



Investment Performance

(In Thousands of New Taiwan Dollars)

DIANTHUS CO.,Ltd			
Statements of Comprehensive Income			
	2021	2022	2023
Sales Revenue	599,944	689,795	695,831
Comprehensive Income	171,767	253,022	14,229
Capital Stock	895,000	895,000	895,000
Investment from Sofiva	148,250	148,250	148,250
Shareholding Ratio of Sofiva	16.56%	16.56%	16.56%
Investment Income of Sofiva	31,047	41,902	23,671



SOFIVA
GENOMICS

SOFIVA GENOMICS Co., Ltd.

www.sofivagenomics.com

T +886-2-2382-6615

F +886-2-2382-6617

Add No.27, Baoqing Rd., Zhongzheng Dist., Taipei City 100